# NKGen Biotech, Inc. · Edgar & Edgarette company card

> NKGen Biotech saw revenue fall 100% in FY2023 to $0 million, operating margin null against a -15.8% median for biological products, (no diagnostic substances), equity -356% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1845459 · fiscal year ended 2023-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/1845459) · [JSON](https://www.pops4.com/boards/company/1845459.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -31618.2%) |
| Net margin | -Infinity% |
| Operating cash flow | −$22M |
| Capital spending | $0 |
| Free cash flow | −$22M |
| Cash | $26,000 |
| Long-term debt | — |
| Total assets | $16M |
| Total equity | −$59M |
| Equity ÷ assets | -356.1% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -59.95 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$20.9M in FY2024)

## Edgarette's reading

Exposure: revenue $0K (FY2023). Experience: revenue down 100.0% on the year; operating margin null, down from -31618.2%. Soundness: equity -356.1% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin null against a -15.8% median; growth -100.0% against 21.4%.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-09-02 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1845459/000121390026096778/0001213900-26-096778-index.htm)
- 8-K · filed 2026-07-17 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1845459/000121390026079235/0001213900-26-079235-index.htm)
- 8-K · filed 2026-06-02 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1845459/000121390026064294/0001213900-26-064294-index.htm)
- 8-K · filed 2026-05-21 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1845459/000121390026060160/0001213900-26-060160-index.htm)
- 8-K · filed 2026-05-04 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1845459/000121390026051727/0001213900-26-051727-index.htm)
- 8-K · filed 2026-04-21 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1845459/000121390026046267/0001213900-26-046267-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001845459.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1845459

## Cite

POPS4, Edgar & Edgarette: NKGen Biotech, Inc. company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/1845459. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2024, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.